{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-008163","form_type":"8-K","ticker":"AURA","cik":"0001501796","company_name":"Aura Biosciences, Inc.","filed_at":"2023-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.288524+00:00","generated_at":"2026-06-18T01:57:17.113639+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aura Biosciences Q4/Full Year 2022 Net Loss $58.8M; Phase 3 Trial on Track, FDA Fast Track for Choroidal Metastasis","bullets":["Net loss of $58.8M for FY2022 vs $35.3M in 2021; cash & securities $188.8M sufficient into 2025.","FDA granted Fast Track Designation for bel-sar in choroidal metastasis, second ocular oncology indication.","Global Phase 3 trial in early-stage choroidal melanoma on track to dose first patient in 1H 2023.","Positive interim Phase 2 data: 100% tumor control rate, statistically significant reduction in growth rate (p<0.0001) at 9-month follow-up.","Raised $92.5M gross proceeds in oversubscribed follow-on public offering in December 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-008163","json":"https://secwatch.observer/filing/0000950170-23-008163.json","markdown":"https://secwatch.observer/filing/0000950170-23-008163.md","text":"https://secwatch.observer/filing/0000950170-23-008163.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501796/000095017023008163/0000950170-23-008163-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501796/000095017023008163/aura-20230315.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T01:57:17.113639+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cd1dba3ecf2acea6b7d22189f5024538df6812fa","claim":"Aura Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.","evidence_excerpt":"issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501796/000095017023008163/0000950170-23-008163-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}